To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Affymax Inc. (NASDAQ:AFFY) lost $0.64 to $6.61 last week after FDA accepted for review an NDA for peginesatide (formerly Hematide) to treat anemia in chronic kidney disease (CKD) patients on dialysis. Affymax and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted the application in May, which would place the PDUFA date around March 2012. The companies did not disclose an actual date.

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.25 (14%) to $1.53 last week after delaying its plans to resubmit an NDA for Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder. The company expects to resubmit on Aug. 8 instead of in July. The company, which received a complete response letter in October, expects a six-month review.

Amgen Inc. (NASDAQ:AMGN) gained $1.27 to $54.70 on Friday after providing several pipeline updates along with earnings. The biotech said it received complete response letters for two sBLAs for Vectibix

Read the full 1509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers